These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6803297)

  • 1. Hemophilia treatment: its relationship to blood products.
    Aledort LM; Goodnight SH
    Prog Hematol; 1981; 12():125-41. PubMed ID: 6803297
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of hemophiliacs with inhibitors: cost and effect on blood resources.
    Aledort LM; Cohen M; Hilgartner M; Lipton R
    Prog Clin Biol Res; 1984; 150():353-65. PubMed ID: 6431439
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of hemophilia].
    Stavem P; Hjort PF
    Tidsskr Nor Laegeforen; 1970 Jul; 90(13):1413-8. PubMed ID: 5453192
    [No Abstract]   [Full Text] [Related]  

  • 4. Specific therapy in hemophilia.
    Hutaff LW
    N C Med J; 1973 Mar; 34(3):193-6. PubMed ID: 4510809
    [No Abstract]   [Full Text] [Related]  

  • 5. Factor products in the treatment of hemophilia.
    Miller KL
    J Pediatr Health Care; 2004; 18(3):156-7. PubMed ID: 15129219
    [No Abstract]   [Full Text] [Related]  

  • 6. [Substitution therapy with factor 8 and factor IX preparations].
    Landbeck G
    Hamatol Bluttransfus; 1968; 5():29-42. PubMed ID: 5729465
    [No Abstract]   [Full Text] [Related]  

  • 7. [Blood derivatives in the treatment of hemophilia in Spain. Present and future needs].
    Medarde A; Ayesa C; Alfonso L; Muñóz A
    Sangre (Barc); 1979; 24(5-C):942-6. PubMed ID: 121170
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of haemophilia.
    Ludlam CA
    Br J Haematol; 1998 May; 101 Suppl 1():13-4. PubMed ID: 9607736
    [No Abstract]   [Full Text] [Related]  

  • 9. Hemophilia.
    Kashyap R; Choudhry VP
    Indian Pediatr; 2000 Jan; 37(1):45-53. PubMed ID: 10745388
    [No Abstract]   [Full Text] [Related]  

  • 10. The current approach to hemophilia.
    Morrison CJ
    J Maine Med Assoc; 1974 Sep; 65(9):205-6. PubMed ID: 4416140
    [No Abstract]   [Full Text] [Related]  

  • 11. [Oral administration of factor VIII or IX concentrate preparation].
    Sakuragawa N
    Rinsho Ketsueki; 1985 Jul; 26(7):1086-9. PubMed ID: 3932721
    [No Abstract]   [Full Text] [Related]  

  • 12. [Technic of obtaining the antihemophilic factors VIII and IX and their clinical application].
    Triginer J; Vila M; Vicente Arangüena P
    Sangre (Barc); 1979; 24(5-C):937-41. PubMed ID: 121169
    [No Abstract]   [Full Text] [Related]  

  • 13. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 14. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy-induced hepatitis risk in hemophilia patients].
    Schiller WG; Renger FG
    Z Arztl Fortbild (Jena); 1983; 77(19):807-10. PubMed ID: 6417919
    [No Abstract]   [Full Text] [Related]  

  • 16. [Advances in the field of hemophilia therapy].
    Loeliger EA; Veltkamp JJ
    Ned Tijdschr Geneeskd; 1968 Sep; 112(36):1593-5. PubMed ID: 5680135
    [No Abstract]   [Full Text] [Related]  

  • 17. Management and surveillance of the hemophiliacs at the National Institute of Hematology and Blood Transfusion of Vietnam.
    Bach QT; Colab
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():113-5. PubMed ID: 7886550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of hemophilia in France.
    Allain JP
    Thromb Haemost; 1976 Jun; 35(3):553-8. PubMed ID: 989961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
    Pollmann H
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.